|Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation|
NA Menzies, T Cohen, HH Lin, M Murray, JA Salomon
PLoS medicine 9 (11), e1001347, 2012
|The costs and effectiveness of four HIV counseling and testing strategies in Uganda|
N Menzies, B Abang, R Wanyenze, F Nuwaha, B Mugisha, A Coutinho, ...
Aids 23 (3), 395-401, 2009
|Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical …|
JW Eaton, NA Menzies, J Stover, V Cambiano, L Chindelevitch, A Cori, ...
The Lancet Global Health 2 (1), e23-e34, 2014
|The cost of providing comprehensive HIV treatment in PEPFAR-supported programs|
NA Menzies, AA Berruti, R Berzon, S Filler, R Ferris, TV Ellerbrock, ...
AIDS (London, England) 25 (14), 1753, 2011
|Increasing access to HIV counseling and testing through mobile services in Kenya: Strategies, utilization and cost-effectiveness|
KL Grabbe, N Menzies, M Taegtmeyer, G Emukule, P Angala, I Mwega, ...
Journal of acquired immune deficiency syndromes (1999) 54 (3), 317, 2010
|Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models|
RMGJ Houben, NA Menzies, T Sumner, GH Huynh, N Arinaminpathy, ...
The Lancet Global Health 4 (11), e806-e815, 2016
|The determinants of HIV treatment costs in resource limited settings|
NA Menzies, AA Berruti, JM Blandford
PloS one 7 (11), e48726, 2012
|Cost-effectiveness of different strategies to monitor adults on antiretroviral treatment: a combined analysis of three mathematical models|
D Keebler, P Revill, S Braithwaite, A Phillips, N Blaser, A Borquez, ...
The Lancet Global Health 2 (1), e35-e43, 2014
|Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models|
NA Menzies, GB Gomez, F Bozzani, S Chatterjee, N Foster, IG Baena, ...
The Lancet Global Health 4 (11), e816-e826, 2016
|Progression from latent infection to active disease in dynamic tuberculosis transmission models: a systematic review of the validity of modelling assumptions|
NA Menzies, E Wolf, D Connors, M Bellerose, AN Sbarra, T Cohen, ...
The Lancet Infectious Diseases 18 (8), e228-e238, 2018
|Nowcasting by Bayesian Smoothing: A flexible, generalizable model for real-time epidemic tracking|
SF McGough, MA Johansson, M Lipsitch, NA Menzies
PLoS computational biology 16 (4), e1007735, 2020
|The potential effects of changing HIV treatment policy on tuberculosis outcomes in South Africa: results from three tuberculosis-HIV transmission models|
C Pretorius, NA Menzies, L Chindelevitch, T Cohen, A Cori, JW Eaton, ...
Aids 28, S25-S34, 2014
|Prospects for tuberculosis elimination in the United States: results of a transmission dynamic model|
NA Menzies, T Cohen, AN Hill, R Yaesoubi, K Galer, E Wolf, SM Marks, ...
American journal of epidemiology 187 (9), 2011-2020, 2018
|Catastrophic costs potentially averted by tuberculosis control in India and South Africa: a modelling study|
S Verguet, C Riumallo-Herl, GB Gomez, NA Menzies, RMGJ Houben, ...
The Lancet Global Health 5 (11), e1123-e1132, 2017
|Bayesian methods for calibrating health policy models: a tutorial|
NA Menzies, DI Soeteman, A Pandya, JJ Kim
Pharmacoeconomics 35 (6), 613-624, 2017
|Cost-effectiveness of routine rapid human immunodeficiency virus antibody testing before DNA-PCR testing for early diagnosis of infants in resource-limited settings|
NA Menzies, J Homsy, JYC Pitter, C Pitter, J Mermin, R Downing, ...
The Pediatric infectious disease journal 28 (9), 819-825, 2009
|The importance of heterogeneity to the epidemiology of tuberculosis|
JM Trauer, PJ Dodd, MGM Gomes, GB Gomez, RMGJ Houben, ...
Clinical infectious diseases 69 (1), 159-166, 2019
|The impact of changes in diagnostic testing practices on estimates of COVID-19 transmission in the United States|
VE Pitzer, M Chitwood, J Havumaki, NA Menzies, S Perniciaro, JL Warren, ...
|An efficient estimator for the expected value of sample information|
Medical Decision Making 36 (3), 308-320, 2016
|Characteristics of HIV care and treatment in PEPFAR-supported sites|
S Filler, AA Berruti, N Menzies, R Berzon, TV Ellerbrock, R Ferris, ...
Journal of acquired immune deficiency syndromes (1999) 57 (1), e1, 2011